Navigation Links
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

om Galderma S.A.

Second Quarter 2009 Financial Results

License and collaboration revenue for the second quarter of 2009 increased 63.5% to $2.3 million from $1.4 million for the second quarter of 2008. License and collaboration revenue consists of the amortization of the upfront technology access fees previously paid by our corporate partners, and reimbursements for the funding of research and development activities, and payments for milestones achieved.

The net loss for the second quarter of 2009 was $0.3 million, or $0.01 per share, compared to a net loss of $2.4 million, or $0.11 per share, reported for the second quarter of 2008.

Research and development expenses for the quarter ended June 30, 2009 totaled $1.4 million, compared to $2.4 million for the quarter ended June 30, 2008. The decrease was due to budget reductions at year end 2008 resulting in decreased headcount, and delayed research, development, and clinical expenses.

General and administrative expenses for the quarter ended June 30, 2009 were $1.2 million, compared to $1.6 million in the comparable 2008 period. Employee costs related to general and administrative expenses decreased as a result of staff reductions at year end 2008. Professional services costs increased primarily as a result of increased Sarbanes-Oxley implementation and year end audit costs.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide((R)) compounds, first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infecti
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
4. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
5. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
11. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Age of Unreason," an important book in which author ... business-affecting change. Though an economist, Handy could not have ... our current recession, yet he offers a prescient perspective ... a shift from manufacturing- to a knowledge-based economy. , ...
... challenging, but knowing how to conduct the proper interviews can ... getting the right person. If its a top executive position ... of the candidates background is critical, but having a method ... experiences increases the chances of hiring the right person. ...
... Catalyst International, a global provider of supply ... of platform-independent SCE applications. , ,"We're expanding and ... increasing demand for integrated fulfillment solutions from supplier ... said Jim Treleaven, President and CEO of Catalyst. ...
Cached Biology Technology:The Molecular Organization 2The Molecular Organization 3Improving the Hiring Process 2
(Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... first comprehensive multi-model-based assessment of so-called Durban Platform scenarios, ... the Potsdam Institute for Climate Impact Research (PIK) and ... Durban Platform is the current negotiation track at the ... climate agreement by 2015 to come into effect in ...
... developing a comprehensive data system that can be used ... them with access to chemical toxicity information. ... the "automated profiling system" from existing bioassay data from ... help scientists who are seeking information on chemicals of ...
... continues to support the role of protein in building and ... embracing the important role of protein in the diet. ... out that protein quality really does matter. The latest ... at SupplySide West, the leading destination for the exploration, discovery, ...
Cached Biology News:Success of climate talks vital for 2°C target 2Success of climate talks vital for 2°C target 3Toxicity database under development at Rutgers-Camden 2Protein quality: It matters 2Protein quality: It matters 3
... immunowash microplate washer 100-240 V, is used ... U-, or V-bottom wells. The immunowash microplate ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... RM is specifically designed as a high ... new variable mass compensation allows high shaking ... better aeration and, therefore, faster growth and ... is ideal when high reproducibility is critical ...
...
Biology Products: